The firm's growth in China and pharmaceutical end markets help it beat the Wall Street estimate for revenue and EPS, despite currency headwinds.
The company beat the consensus Wall Street estimate for the fourth quarter on the bottom line but missed the estimate on the top line.
The preliminary revenue results come ahead of the company's planned merger with Takara Bio USA Holdings.
The firm's diagnostics revenues grew 8 percent year over year, and it beat the consensus Wall Street estimates on the top and bottom lines.
The company expects Medicare coverage for its test to extend to intermediate prostate cancer patients this year, and it believes new data will help drive increased adoption.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
Invitae reported $9.2 million in fourth quarter revenues compared to $3.2 million in the year-ago period, beating the consensus Wall Street estimate of $8.8 million.
The firm's full-year 2016 revenues fell 9 percent, also on lower instrument sales.
The firm said the revenue growth was driven by a return to sequential growth in hereditary cancer testing revenue and sales of GeneSight.
The firm reported that revenues for Nanosphere, which Luminex acquired in 2016, were up 39 percent year-over-year.
In Science this week: intellectual property landscape of CRISPR genome editing, and more.
A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.
Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.
Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.